Difference between revisions of "Adagrasib (Krazati)"
Jump to navigation
Jump to search
m (Jwarner moved page Adagrasib (MRTX849) to Adagrasib (Krazati): FDA approval) |
m |
||
| Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adagrasib NCI Drug Dictionary]: An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adagrasib NCI Drug Dictionary]: An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. | ||
| − | == | + | ==Diseases for which it is established== |
*[[Non-small cell lung cancer, KRAS-mutated]] | *[[Non-small cell lung cancer, KRAS-mutated]] | ||
| − | # | + | |
| + | ==History of changes in FDA indication== | ||
| + | *12/12/2022: Granted accelerated approval for adult patients with [[Biomarkers#KRAS|KRAS]] [[Biomarkers#G12C|G12C-mutated]] locally advanced or metastatic [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]], as determined by an FDA-approved test, who have received at least one prior systemic therapy. ''(Based on KRYSTAL-1)'' | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' MRTX849 | *'''Code name:''' MRTX849 | ||
| + | *'''Brand name:''' Krazati | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 13: | Line 16: | ||
[[Category:KRAS inhibitors]] | [[Category:KRAS inhibitors]] | ||
| − | [[Category:Non-small cell lung cancer medications | + | [[Category:Non-small cell lung cancer medications]] |
| − | [[Category: | + | [[Category:FDA approved in 2022]] |
Revision as of 21:13, 26 December 2022
Mechanism of action
From the NCI Drug Dictionary: An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling.
Diseases for which it is established
History of changes in FDA indication
- 12/12/2022: Granted accelerated approval for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. (Based on KRYSTAL-1)
Also known as
- Code name: MRTX849
- Brand name: Krazati